Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2022-03-09 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-03-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an at-the-market equity offering of common shares. It includes detailed information about the offering, sales agreement, risk factors, use of proceeds, and other related disclosures. The document is not a financial report like an annual or quarterly report, nor is it a management discussion or earnings release. It is a capital raising disclosure document describing the terms and conditions of a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is a full financing update filing.
2022-03-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to an at-the-market equity offering sales agreement, detailing the terms of the offering, sales agents, and commission structure. It includes legal opinions and references to registration statements but does not contain financial statements or detailed financial performance data. The document is focused on a capital raising activity and amendment to a financing agreement, which fits the category of Capital/Financing Update rather than a full financial report or other categories. The length (6474 characters) and detailed description of the financing amendment support this classification with high confidence.
2022-03-01 English
10-K
Annual Report FY 2021
2022-03-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company announced its financial results for the year ended December 31, 2021, via a press release attached as an exhibit. The document itself does not contain the full financial report or detailed financial statements but rather furnishes the press release. The length is 3395 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing or furnishing a press release of financial results without containing the full report is classified as a Regulatory Filing (RNS).
2022-03-01 English
SCHEDULE 13G (AMENDMENT NO. 1)
Major Shareholding Notification
2022-02-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.